Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2013
At a glance
- Drugs SR 31747 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ODYSSEY
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2008 Actual initiation date (Oct 2003) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.